ALK-negative anaplastic large cell lymphoma
ALK-negative anaplastic large cell lymphoma
Explore linked clinical trials. Standard reference: MONDO:00176036 results ยท Page 1 of 1
Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| Constitutive IL7R (C7R) Modified Banked Allogeneic CD30.CAR EBVSTS for CD30-Positive Lymphomas | ALK-negative anaplastic large cell lymphoma, ALK-positive anaplastic large cell lymphoma, Hemic and Lymphatic Diseases, Hodgkins lymphoma, Neoplasms by Histologic Type, T-cell non-Hodgkin lymphoma, anaplastic large cell lymphoma, immune system disorder, immunoproliferative disorder, lymphatic system disorder, lymphoma, lymphoproliferative syndrome, mature T-cell and NK-cell non-Hodgkin lymphoma, neoplasm, non-Hodgkin lymphoma | Recruiting | Phase 1 | 2026-10-02 | NCT06176690 | |
| Testing Whether High Dose Chemotherapy and Infusion of the Patients' Own Stem Cells Improves Survival in Patients With Peripheral T-cell Lymphoma Who Achieved a Complete Response at the End of the Initial Chemotherapy | ALK-negative anaplastic large cell lymphoma, Hemic and Lymphatic Diseases, Neoplasms by Histologic Type, T-cell non-Hodgkin lymphoma, anaplastic large cell lymphoma, immune system disorder, immunoproliferative disorder, lymphatic system disorder, lymphoma, lymphoproliferative syndrome, neoplasm, peripheral T-cell lymphoma, not otherwise specified | Recruiting | Phase 3 | 2026-09-14 | NCT06724237 | |
| Brentuximab Vedotin and Combination Chemotherapy in Treating Patients With CD30-Positive Peripheral T-cell Lymphoma | ALK-negative anaplastic large cell lymphoma, ALK-positive anaplastic large cell lymphoma, Hemic and Lymphatic Diseases, Lymphadenopathy, Neoplasms by Histologic Type, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Precursor T-Cell Lymphoblastic Leukemia-Lymphoma, T-cell non-Hodgkin lymphoma, adult T-cell leukemia/lymphoma, anaplastic large cell lymphoma, angioimmunoblastic T-cell lymphoma, enteropathy-associated T-cell lymphoma, hematologic disorder, hepatosplenic T-cell lymphoma, immune system disorder, immunoproliferative disorder, leukemia, lymphatic system disorder, lymphoid leukemia, lymphoma, lymphoproliferative syndrome, mature T-cell and NK-cell non-Hodgkin lymphoma, neoplasm, peripheral T-cell lymphoma, not otherwise specified | Active, not recruiting | Phase 2 | 2026-08-21 | NCT03113500 | |
| Talimogene Laherparepvec and Nivolumab in Treating Patients With Refractory Lymphomas or Advanced or Refractory Non-melanoma Skin Cancers | ALK-negative anaplastic large cell lymphoma, ALK-positive anaplastic large cell lymphoma, Colorectal Neoplasms, Hereditary Nonpolyposis, Congenital, Hereditary, and Neonatal Diseases and Abnormalities, DNA Virus Infections, Hemic and Lymphatic Diseases, Infections, Lynch syndrome 2, Muir-Torre syndrome, Neoplasms by Histologic Type, Neoplasms by Site, Neoplasms, Ductal, Lobular, and Medullary, Neoplasms, Germ Cell and Embryonal, Neoplasms, Nerve Tissue, Sezary syndrome, Skin and Connective Tissue Diseases, T-cell non-Hodgkin lymphoma, Tumor Virus Infections, adenocarcinoma, anaplastic large cell lymphoma, apocrine adenocarcinoma, basal cell carcinoma, basal cell neoplasm, basosquamous carcinoma, carcinoma, cutaneous neuroendocrine carcinoma, cystic, mucinous, and serous neoplasm, eccrine porocarcinoma, epithelial neoplasm, extramammary Paget disease, hereditary disease, hereditary neoplastic syndrome, hereditary skin disorder, hidradenocarcinoma, immune system disorder, immunoproliferative disorder, lymphatic system disorder, lymphoma, lymphoproliferative syndrome, malignant syringoma, mycosis fungoides, neoplasm, neuroendocrine carcinoma, neuroendocrine neoplasm, papillary adenocarcinoma, polyomavirus infectious disease, primary cutaneous T-cell non-Hodgkin lymphoma, primitive neuroectodermal tumor, sebaceous gland disorder, sebaceous gland neoplasm, signet ring cell carcinoma, skin basal cell carcinoma, skin disorder, skin neoplasm, skin squamous cell carcinoma, sweat gland cancer, sweat gland carcinoma, viral infectious disease, vulvar squamous cell carcinoma | Active, not recruiting | Phase 2 | 2026-08-13 | NCT02978625 | |
| Autologous IC-Nine, CD30 CAR, and Constitutive IL7R Expressing EBVST for CD30 Lymphoma (ANCILE-30) | ALK-negative anaplastic large cell lymphoma, ALK-positive anaplastic large cell lymphoma, B-cell neoplasm, Hemic and Lymphatic Diseases, Hodgkins lymphoma, Neoplasms by Histologic Type, T-cell non-Hodgkin lymphoma, anaplastic large cell lymphoma, diffuse large B-cell lymphoma, immune system disorder, immunoproliferative disorder, lymphatic system disorder, lymphoma, lymphoproliferative syndrome, mature T-cell and NK-cell non-Hodgkin lymphoma, neoplasm | Not yet recruiting | Phase 1 | 2026-07-27 | NCT07729397 | |
| A Registry for People With T-cell Lymphoma | ALK-negative anaplastic large cell lymphoma, ALK-positive anaplastic large cell lymphoma, Hemic and Lymphatic Diseases, Leukemia, Large Granular Lymphocytic, Lymphadenopathy, Lymphoma, Extranodal NK-T-Cell, Neoplasms by Histologic Type, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Precursor T-Cell Lymphoblastic Leukemia-Lymphoma, Sezary syndrome, T-cell leukemia, T-cell non-Hodgkin lymphoma, T-cell prolymphocytic leukemia, adult T-cell leukemia/lymphoma, aggressive NK-cell leukemia, anaplastic large cell lymphoma, angioimmunoblastic T-cell lymphoma, breast implant-associated anaplastic large cell lymphoma, enteropathy-associated T-cell lymphoma, extranodal nasal NK/T cell lymphoma, hematologic disorder, hepatosplenic T-cell lymphoma, hydroa vacciniforme-like lymphoma, immune system disorder, immunoproliferative disorder, leukemia, lymphatic system disorder, lymphoid leukemia, lymphoma, lymphoproliferative syndrome, monomorphic epitheliotropic intestinal T-cell lymphoma, mycosis fungoides, neoplasm, peripheral T-cell lymphoma, not otherwise specified, primary cutaneous T-cell lymphoma, primary cutaneous T-cell non-Hodgkin lymphoma, primary cutaneous anaplastic large cell lymphoma, prolymphocytic leukemia, subcutaneous panniculitis-like T-cell lymphoma | Recruiting | Not stated | 2026-05-20 | NCT05978141 |